I don't understand this management. They keep silent about the issues stockholders care about. They do not tell us anything, and I mean anything about their quest for financing of Ovadx tests, their progress toward getting Ovadx or Parkinsons approval with the FDA, and then they issue a 10k report which is absolutely silent about the same issues. And they are producing significantly less revenue without explanation. The 10k is one of the most negative statements of operations that I have encountered in my investing career of many, many years. I believe the stock will close tomorrow somewhere from 8 cents to 12 cents a share.
Market Data 
Markets 
AI
